Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Enterprise Value (2022 - 2025)

BioXcel Therapeutics has reported Enterprise Value over the past 4 years, most recently at -$28.8 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$28.8 million for Q4 2025, up 3.67% from a year ago — trailing twelve months through Dec 2025 was -$28.8 million (up 3.67% YoY), and the annual figure for FY2025 was -$28.8 million, up 3.67%.
  • Enterprise Value for Q4 2025 was -$28.8 million at BioXcel Therapeutics, up from -$37.3 million in the prior quarter.
  • Over the last five years, Enterprise Value for BTAI hit a ceiling of -$18.6 million in Q2 2025 and a floor of -$233.5 million in Q2 2022.
  • Median Enterprise Value over the past 4 years was -$69.7 million (2023), compared with a mean of -$101.5 million.
  • Peak annual rise in Enterprise Value hit 66.99% in 2025, while the deepest fall reached 3.67% in 2025.
  • BioXcel Therapeutics' Enterprise Value stood at -$193.7 million in 2022, then skyrocketed by 66.33% to -$65.2 million in 2023, then surged by 54.23% to -$29.9 million in 2024, then rose by 3.67% to -$28.8 million in 2025.
  • The last three reported values for Enterprise Value were -$28.8 million (Q4 2025), -$37.3 million (Q3 2025), and -$18.6 million (Q2 2025) per Business Quant data.